Terumo Corporation Reports Strong Revenue Growth Despite Decline in Comprehensive Income

Terumo ( (JP:4543) ) has shared an update.

Terumo Corporation reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a significant increase in revenue and operating profit compared to the previous year. The company achieved a 12.4% rise in revenue to 1,036,171 million yen and a 12.5% increase in operating profit to 157,668 million yen. Despite these positive results, total comprehensive income saw a substantial decline of 58.7%. The company also announced a two-for-one share split effective April 1, 2024, impacting earnings per share calculations. Looking ahead, Terumo projects continued growth with a modest increase in revenue and a significant rise in profit for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

More about Terumo

Terumo Corporation is a leading company in the healthcare industry, primarily focusing on the development and manufacturing of medical devices and equipment. The company is listed on the Tokyo Stock Exchange and is known for its innovative solutions in medical technology, serving a global market with a strong emphasis on quality and safety.

Average Trading Volume: 3,782,173

Technical Sentiment Signal: Buy

Current Market Cap: Yen4087.6B

Find detailed analytics on 4543 stock on TipRanks’ Stock Analysis page.